{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1+Dose+Level+3&page=2", "query": { "intervention": "Phase 1 Dose Level 3", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1+Dose+Level+3&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-21T12:31:05.523Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00928083", "title": "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malaria Falciparum", "Malaria Vivax", "Healthy Volunteers" ], "interventions": [ { "name": "OZ439 50mg API capsules", "type": "DRUG" }, { "name": "OZ439 200mg API capsules", "type": "DRUG" }, { "name": "OZ439 400mg aqueous dispersion", "type": "DRUG" }, { "name": "OZ439 800mg aqueous dispersion", "type": "DRUG" }, { "name": "OZ439 100mg API capsules", "type": "DRUG" }, { "name": "OZ439 400mg API capsules", "type": "DRUG" }, { "name": "OZ439 1600mg aqueous dispersion", "type": "DRUG" }, { "name": "OZ439 800mg API capsules", "type": "DRUG" }, { "name": "OZ439 1200mg API capsules", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "OZ439 200mg aqueous dispersion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medicines for Malaria Venture", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 63, "start_date": "2009-04", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2015-01-08", "last_synced_at": "2026-09-21T12:31:05.523Z", "location_count": 1, "location_summary": "Miramar, Florida", "locations": [ { "city": "Miramar", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00928083" }, { "nct_id": "NCT01154387", "title": "Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "End Stage Renal Disease", "Renal Transplant" ], "interventions": [ { "name": "Anti-Thymocyte Globulin", "type": "DRUG" }, { "name": "TOL101", "type": "DRUG" }, { "name": "Steroids", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tolera Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 85, "start_date": "2010-07", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2013-06-11", "last_synced_at": "2026-09-21T12:31:05.523Z", "location_count": 12, "location_summary": "Aurora, Colorado • Lexington, Kentucky • Ann Arbor, Michigan + 9 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Livingston", "state": "New Jersey" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01154387" }, { "nct_id": "NCT01296763", "title": "Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Irinotecan", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Olaparib (for levels 1 and 5)", "type": "DRUG" }, { "name": "Olaparib (for dose level 2)", "type": "DRUG" }, { "name": "Mitomycin-C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2011-01", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2016-03-22", "last_synced_at": "2026-09-21T12:31:05.523Z", "location_count": 2, "location_summary": "Baltimore, Maryland • New York, New York", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01296763" }, { "nct_id": "NCT01677845", "title": "Hypo-Fractionated Radiation Therapy for Localized Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 9, "start_date": "2012-05", "completion_date": "2017-08-25", "has_results": false, "last_update_posted_date": "2017-08-28", "last_synced_at": "2026-09-21T12:31:05.523Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01677845" }, { "nct_id": "NCT04108195", "title": "A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "Talquetamab", "type": "DRUG" }, { "name": "Teclistamab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 290, "start_date": "2020-02-21", "completion_date": "2027-04-07", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-21T12:31:05.523Z", "location_count": 10, "location_summary": "Duarte, California • Irvine, California • San Francisco, California + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04108195" }, { "nct_id": "NCT05774639", "title": "Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Idiopathic Urticaria" ], "interventions": [ { "name": "Omalizumab Injection", "type": "DRUG" }, { "name": "Xolair Prefilled Syringe", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kashiv BioSciences, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 600, "start_date": "2023-08-15", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2025-02-05", "last_synced_at": "2026-09-21T12:31:05.523Z", "location_count": 4, "location_summary": "Brandon, Florida • Brooksville, Florida • Miami Lakes, Florida + 1 more", "locations": [ { "city": "Brandon", "state": "Florida" }, { "city": "Brooksville", "state": "Florida" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "West Lafayette", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05774639" }, { "nct_id": "NCT00046839", "title": "Celecoxib and Radiation Therapy in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "celecoxib", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2002-07", "completion_date": null, "has_results": true, "last_update_posted_date": "2015-11-17", "last_synced_at": "2026-09-21T12:31:05.523Z", "location_count": 44, "location_summary": "Colorado Springs, Colorado • Gainesville, Florida • Jacksonville, Florida + 37 more", "locations": [ { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Rome", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00046839" }, { "nct_id": "NCT02241187", "title": "Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "PEGPH20", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "DW & DCE-MRI", "type": "DEVICE" }, { "name": "blood draws", "type": "OTHER" } ], "intervention_types": [ "DRUG", "DEVICE", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2014-09-12", "completion_date": "2016-09-13", "has_results": true, "last_update_posted_date": "2017-09-27", "last_synced_at": "2026-09-21T12:31:05.523Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02241187" }, { "nct_id": "NCT00850993", "title": "A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hyperbilirubinemia, Neonatal" ], "interventions": [ { "name": "Stannsoporfin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "PhotoTherapy (as needed)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Minute", "maximum_age": "48 Hours", "sex": "ALL", "summary": "1 Minute to 48 Hours" }, "enrollment_count": 58, "start_date": "2008-08", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2019-10-30", "last_synced_at": "2026-09-21T12:31:05.523Z", "location_count": 9, "location_summary": "Colton, California • San Diego, California • Honolulu, Hawaii + 5 more", "locations": [ { "city": "Colton", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00850993" }, { "nct_id": "NCT01419197", "title": "A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Trastuzumab emtansine", "type": "DRUG" }, { "name": "Treatment of physician's choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 602, "start_date": "2011-09", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-10-12", "last_synced_at": "2026-09-21T12:31:05.523Z", "location_count": 59, "location_summary": "Tucson, Arizona • Hot Springs, Arkansas • Hayward, California + 52 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Hayward", "state": "California" }, { "city": "Highland", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01419197" } ] }